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1. SUMMARY 
 
 
 
The rapid rise in the prevalence of chronic renal diseased has turned one of the major 
healthcare problems. These diseases are hard to be diagnosed in the initial phase, they lead to 
an impaired quality of life, and more than 50% of the patients die of cardiovascular disease 
before the onset of renal impairment. Therefore, their prevention is of great importance. 
I have chosen iatrogenic renal diseases as the topic of my doctoral theses. In my work, 
I have focused mainly on the role of drugs, paramedical products, herb extracts and contrast 
materials. 
Out of the drug-induced nephropathies, I have concentrated on analgesic nephropathy 
induced by the use of combined analgesics. The main cause for this was, that according to a 
report sent in the first half of the 1990's, this disease was supposed to be rare in Hungary. On 
the other hand, by the start of my work, many phenacetin-containing drugs were sold in an 
over-the-counter manner. In other countries with similar marketing strategies, a marked 
prevalence of analgesic nephropathy has been reported. Thus, we have conducted a national 
survey with support of the Hungarian Society of Nephrology to evaluate the prevalence of 
analgesic nephropathy. 
According to or results, there was a 14.8% prevalence of analgesic nephropathy in 
patients with  end-stage renal diseases with unknown diagnosis in the background of renal 
failure. Majority of the patients were females, who have consumed phenacetin-containing 
analgesic mixtures due to diseases leading to chronic pain, mainly headache. The prevalence 
of myocardial infarction was significantly higher in patients consuming combined analgesics 
than in those not taking this type of drugs. 
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We have also evaluated the psychiatric personality characteristics of patients with 
analgesic nephropathy, to screen for alterations predisposing to the abuse of analgesics. 
According to our results, these patients show a higher rate of unrecognized and untreated 
depression than other patients with renal disease. The patients received mainly 
pychofarmacons (sedatives and anxiolytics), that did not improve the abuse of analgesics. 
Finally, we demonstrate the potential nephrotoxic effect of herb products by reporting 
the case of a woman consuming Guarana extract presenting with a renal failure. 
With my work, I would like to draw attention to the frequency and the prevention of 
iatrogenic renal diseases. 
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2. INTRODUCTION 
 
 
 
A fast rise in the number of patients with renal diseases has been observed in the last decade. 
The renal damage developed in relation with medical activity is called iatrogenic renal 
damage. In the background of acute iatrogenic renal damage we may find diagnostic 
procedures (e.g. abdominal angiography), numerous medications (e.g. non-steroid anti-
inflammatory drugs – NSAID –, angiotensin-converting enzyme inhibitors – ACEI –, 
antibiotics, analgesics, diuretics), diagnostics (e.g. X-ray contrast materials) and therapeutic 
interventions (e.g. methods of interventional radiology, vascular operations. Iatrogenic renal 
damage may develop in 2-5% of patients treated for another disease and in up to 23% of 
patients treated on an Intensive Care Unit. The rise in chronic renal failure may be accounted 
for by the rise in life expectancy, the rise in the prevalence of diabetes mellitus and 
hypertension as well as iatrogenic damages due to medical interventions. As a consequence of 
a much wider availability of diagnostic and therapeutic procedures, renal damage may 
develop, that may be preventable. If we take the high cost of renal replacement therapies into 
consideration, then besides the frequent diseases that predispose to end-stage renal failure 
(diabetes mellitus, hypertension, polycystic kidney diseases, chronic glomerulonephritis etc.), 
also iatrogenic effects, especially those caused by drugs (analgesic nephropathy etc.), 
paramedical preparations, herb extracts and radiocontrast materials deserve special attention. 
Recently, in the last years it has been recognized that in patients with chronic renal failure 
gadolinium may lead to a preventable disease, the so-called nephrogenic systemic fibrosis 
(NSF). 
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3. HYPOTHESES AND AIMS 
 
 
 
Hypotheses: 
 
1. As a consequence of the domestic characteristics of analgesic supply (a high number 
of phenacetin-containing medications) and the easy availability of the drugs, it is 
probable, that also in Hungary a lot of patients suffer from analgesic nephropathy and 
a part of these patients may eventually require renal replacement therapy. 
2. We assume that a part of the Hungarian patients with analgesic nephropathy present 
signs of an impaired personality that may predispose them to the chronic consumption 
of (combined) analgesics. 
3. A lot of herb products are marketed in Hungary for the improvement of performance 
and preservation of health that may in fact have a potentially nephrotoxic effect. 
 
Aims: 
 
1. Measurement of the prevalence of analgesic nephropathy among patients initiating 
renal replacement therapy in Hungary. 
2. Analysis of markers of personality among patients with analgesic nephropathy in 
collaboration with psychiatrists. 
3. To find a subject in our nephrological medical care, whose renal disease was 
associated with a herbal product and present his/her case.  
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4. STUDY DETAILS 
 
 
 
4.1. The prevalence of analgesic nephropathy 
 
In 1997, we have conducted a national survey; the study was named Hungarian 
Analgesic Nephropathy Study (HANS). The aim was to measure the nation-wide prevalence, 
causes, clinical characteristics of analgesic nephropathy among patients initiating renal 
replacement therapy, and the composition of drugs. Without such data, we were unable to 
initiate the withdrawal of phenacetin from marketing, and to make a part of the analgesics 
prescription-bound. Only in possession of the results could we hope to protect the Hungarian 
society from a preventable disease. 
 
 Patients and methods 
The study has been carried out according to the criteria of the earlier Belgium-centered 
European multicentre study, the Analgesic Nephropathy Network Europe (ANNE). Twenty-
two of the eligible 52 dialysis units in Hungary have participated in the study. Over 3 years 
(January 1st 1995. – January 1st 1998.) all adult patients over the age of 20 years initiating 
dialysis have been included to study the prevalence of analgesic nephropathy in the 
background of the development of chronic renal failure. Dialysis units form all parts of the 
country – also three of the four units located at university centers – were included to make 
sure that our result are representative for the entire country. Large cities were represented by 
Budapest and three cities with 100,000 - 200,000 inhabitants, while all other units represented 
larger cities and rural regions. The study was initiated after the permission of the local Ethical 
Board and on the basis of written informed consent. 
 8
Patients with established glomerulonephritis, polycystic kidney disease, diabetic 
nephropathy and other systemic diseases (SLE, Henoch-Schönlein syndrome, vasculitis) or 
hypertensive nephrosclerosis or those with a kidney disease diagnosed upon a renal biopsy 
were excluded from the study. Those patients who had lacking or incomplete data or who 
have died prior to the collection of all required data were also excluded from the statistical 
analysis, i.e. only patients initiating renal replacement therapy because of an unknown kidney 
disease have only been enrolled into the study. 
 
The diagnosis of analgesic nephropathy was established upon the criteria used in the 
ANNE study. 
1. Medication history 
We have used following methods to detect abuse of analgesics: 
a) An interview based on a questionnaire including potential complaints (frequent headache 
and pain on menstruation, chronic joint pain, chronic inflammatory bowel diseases, or any 
type of long-lasting or recurring pain) and medication taking habits (type of medication, dose 
and duration).  
b) All patients were asked to read through a booklet containing images of the package of all 
„suspicious” analgesic and NSAID drugs sold between 1970 and 1995, asking them to select 
the drugs that he/she was taking. 
c) Finally, in case of suspect, when the patient himself was denying taking such 
medications, also relatives were asked on the medication-taking habits of the patients.  
We defined chronic analgesic abuse as a regular, daily consumption of 1-25 tablets or 
powder containing (combined) analgesics for at least 5 years. Combined analgesics contained 
at least two sorts of analgesics (phenacetin/paracetamol and pyrasolon-derivatives or aspirin) 
and one agent inducing dependence (caffeine and/or codein). 
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2. Imaging techniques 
Patients enrolled in the study underwent ultrasound investigation and/or a CT-scan without 
contrast-material. Using the criteria of the ANNE (Analgesic Nephropathy Network Europe) 
study, we suspected analgesic nephropathy,  if: 
a.) the sum of the horizontal and vertical diameters of the kidney were <103mm in males 
or <96 mm in females; 
b.) if the contour of the kidney was irregular, wavy and at least 3 retractions could be seen 
on the surface; 
c.) we could observe calcification of renal papillae. 
To establish the diagnosis, the presence of alterations listed in a+b or a+c was required.  
We have also collected data on smoking habits and serum lipid and blood pressure values of 
the patients positive upon the criteria, and we also recorded cardiovascular and 
cerebrovascular events (acute myocardial infarct, stroke) in their history. 
 
Statistical analysis of the data 
Statistical evaluation of the data has been carried out using SPSS 8.0 for Windows, using 
standard statistical procedures. 
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Results 
HANS was the first study in Hungary to analyse the prevalence of analgesic 
nephropathy in a representative sample using uniform, objective criteria. Using the diagnostic 
criteria of the former European ANNE study (chronic analgesics abuse and positive renal 
imaging), 3.3% of patients initiating dialysis had analgesic nephropathy in this period. This 
data is approximately three times higher than the number reported form Hungary in the ERA-
EDTA registry. The proportion was markedly higher (14.8%) in patients initiating dialysis 
upon an unknown diagnosis. Patients were taking mainly phenacetine-containing combined 
analgesics, mainly for chronic headache. The prevalence of acute myocardial infarction was 
significantly higher in patients regularly consuming combined analgesics compared to 
patients not receiving these drugs (15 vs. 5%, p<0.01). 
 
4. 2 Psychiatric study of patients with analgesic nephropathy  
In our study, we have intended to find some sort of psychic alteration in the background of 
chronic drug consumption leading to analgesic nephropathy. On the other hand, we planned to 
characterize the personality of the patients. As chronic somatic diseases may present a high 
risk for the development of secondary psychiatric symptoms, patients having chronic renal 
failure for at least 10 years served as controls. 
Patients and methods 
The study has been carried out with the permission of the local Ethical Board in 9 Hungarian 
dialysis units, also participating in HANS. We have analyzed the personality of 47 patients 
diagnosed with analgesic nephropathy as cases, and 57 patients with more than 10 years 
established chronic renal disease as controls. Out of the 104 patients, 69 underwent chronic 
dialysis, while 35 patients were in ambulant patient care, not yet requiring renal replacement 
therapy.  
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During the psychiatric and somatic interview, we collected data on the presence of 
psychiatric diseases in the family or in the patients’ case history, and on psychopharmacons 
consumed by the patient at the time of analysis of prior to that. We have used a list of 
symptoms and two tests for the survey of psychological characteristics of the patients. In the 
list of symptoms, we can find 36 frequent somatisation symptoms (pain, vegetative signs of 
anxiety etc. and psychic complaints: anxiety, problems with concentration, forgetfulness etc.) 
were listed, and patients reported prevalence of these symptoms within the past month. 
Tests: 
1. A Beck Depression Inventory is a self-check multiple-choice test with 22 questions 
containing the major somatic (weight loss, asitia, sleep disorder, fatigue, sexual disorders) and 
psychic components (hopelessness, self-accusation, remorse, sadness, feeling insufficient 
etc.).  
2. We used the Ammon’s Ego-Structure test to examine the patients personality traits.  
Statistical analysis of the data 
 Microsoft Excel 7.0 and SPSS for Windows 8.0 were used for the analysis of the test 
sheets and the statistical analysis, respectively, we used Mann-Whitney u test and crosstabs (χ2 
–test) for the analyses.  
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Results 
Examining the patients’ psychiatric characteristics, it was found that psychological 
problems occurred more frequently in the family histories (14.9 vs. 7.0 %) as well as personal 
case histories (36.2 vs. 8.8 % p<0.001) than in patients with other renal diseases. Depression 
was the most frequent among the earlier psychiatric disorders, affecting nearly 30% of 
patients with analgesic nephropathy compared to other renal diseases (29.8 vs.7.0%, p <0.01). 
During their lifetime, nearly two third of the patients has regularly consumed 
phsychopharmacons, while only slightly more than one quarter of the control group. Among 
the psychopharmacons, sedatohypnotics (mainly benzodiazepines and meprobamate) were the 
most frequent in both groups, while the proportion of mood stabilizers was markedly lower. 
Interestingly, at the time of the study, there was no more significant difference in the 
use of psychopharmacons, and more than one third of the patients has received psychiatric 
medication. Distribution of the current drugs was similar to that observed by the previous 
drugs. Concerning items of the symptom list, patients suffering from analgesic nephropathy 
reported more somatic (10.80 vs. 7.32 symptoms, p <0.01) and psychological problems (4.53 
vs. 3.35 symptoms p <0.08). There was a significantly higher rate of headache, vertigo, 
weakness, palpitation and digestive problems as well as sleeping disorders, weariness, 
nervousness, forgetfulness and inability of making decision in cases than in controls. 
Patients with analgesic nephropathy also had a higher score in the Beck test (12.6 vs. 
10.36; p <0.05). Considering the total score of the test, the number of cases free of symptoms 
of depression (score <9) was significantly lower than that for controls (34.0 vs. 54.4 %, 
p<0.05) We have also found a difference between the two groups in more factors of the 
Ammon’s Ego-Structure-Test. Patients with analgesic nephropathy had lower scores of 
constructive aggression and anxiety as well as inner and outer self-limitation; while they had 
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significantly higher scores for destructive anxiety as well as destructive and deficite 
narcissism compared to controls. 
 
4.3 RENAL DAMAGE INDUCED BY HERB EXTRACTS AND PARAMEDICAL AGENTS 
 
 Many plant are known to be able to induce renal damage. The damage may develop 
upon many ways, most significant of which is an allergic reaction, direct or inderect toxicity 
or interaction with other paramedical preparates, hormones er heavy metals. 
We report the case of a 30 years old female patient, who was admitted to our 
department because of acute renal failure and elevated level of liver enzymes. In the 
background of her symptoms, we have histologically diagnosed acute renal tubular necrosis 
that may have developed due to the combined intake of Guarana and Algopyrin. After 
omission of the drugs and transient hemodialysis sessions, the acute renal failure has gone 
into remission, and the general state of the patient has improved.  
 Using this case, we would like to draw attention to potential renal damage-inducing 
ability of widely marketed paramedical preparations, herb extracts. These herb extracts may 
be purchased in pahrmacies or drogeries without a prescription, may be ordered electronically 
via the internet, and their composition, purity, active substance content are much less 
controlled and regulated than that of regular medications. 
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5. LIST OF DOCTORAL THESES 
 
 
 
1. According to HANS – the national analgesic nephropathy survey –, we can found 
analgesic nephropathy in the background o fend-stage renal disease in 14.8% of patients 
initiating renal replacement therapy with an unknown renal disease. 
 
2. The patients were mainly consuming phenacetin-containing combined analgesics, 
mainly due to chronic headache. 
 
3. The prevalence of acute myocardial infarction was significantly higher in patients 
regularly consuming combined analgesics. 
 
4. Both somatic and psychological symptoms were significantly more prevalent in the 
personal as well as in the family history of patients with analgesic nephropathy; leading 
symptoms were depression and anxiety. Patients with analgesic nephropathy treat their 
problems and symptoms with psychopharmacons (mainly sedatives and anxiolytics), their 
depression is rarely recognized and they rarely receive an adequate therapy. 
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6. CONCLUSIONS, PLANS FOR THE FUTURE 
 
 
 
1. Results of the HANS study and data of the literature indicate that phenacetin is harmful 
for the kidneys and leads to analgesic nephropathy in a marked percent of case in 
Hungary, as well. Our study conducted with the support of the Hungarian Society of 
Nephrology has contributed to the fact that phenacetin was replaced by other analgesics in 
the latest edition of Formulae Normales. Only two phenacetin-containing company-
products are currently being sold (Antineuralgica and Dolor), and they may not be 
marketed over-the-counter. On the other hand – unfortunately – Algopyrin, an agent with 
a less toxic side-effect profile and good painkiller properties has also turned prescription-
only. Therefore patients with chronic pain syndroms consume prescription-free marketed 
NSAIDs at even larger proportions (thanks to a great contribution of TV-commercial 
spots, too), which are well-known to be nephrotoxic. As the major cause for taking 
analgesics is headache from the chronic pain syndromes, we plan to screen patients of 
„headache patient care units” beside pain- and rheumatologic outpatient units for 
analgesic nephropathy. 
 
2. The anxiety-depression syndrome observed in our patients with analgesic nephropathy 
may contribute to the abuse of analgesics. Therefore we plan to treat these patients in 
collaborations with our psychiatrist colleagues. In a further step, we plan to evaluate 
analgesic abuse and to perform nephrological screening of patients presenting with 
anxiety-depression symptoms at psychiatric outpatient units.  
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3. As a consequence of the widening field of diagnostic and therapeutic possibilities as well 
as that of complimentary medicine, there is an increasing prevalence of iatrogenic renal 
damage, the prevention of which should be focused more on. We would like to draw 
attention to the prevention of iatrogenic renal damage with the inclusion of colleagues 
from other fields such as rheumatology, neurology, radiology, psychiatry as well as 
presenting lectures for general practitioners and writing papers published in national 
medical educational journals. 
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